Intravesical Immunotherapy Shows Recurrence Control in BCG-Unresponsive Papillary-Only Non–Muscle-Invasive Bladder Cancer

Intravesical treatment with cretostimogene grenadenorepvec (CG0070) shows promising efficacy in high-risk, papillary-only, BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), demonstrating high-grade recurrence-free survival rates of 95.7% at 3 months and 80.4% at 9 months. Presented by Dr. Mark D. Tyson II at the SUO Annual Meeting, the phase III BOND-003 study indicates the treatment is well-tolerated with most adverse events being mild. With ongoing follow-up and an FDA submission in progress, CG0070 has the potential to reshape treatment options for high-risk NMIBC patients.